Orion Health Group Limited Independent Adviser’S Report and Independent Appraisal Report
Total Page:16
File Type:pdf, Size:1020Kb
Orion Health Group Limited Independent Adviser’s Report and Independent Appraisal Report September 2018 STATEMENT OF INDEPENDENCE KordaMentha confirms that it: (a) has no conflict of interest that could affect its ability to provide an unbiased report; and (b) has no direct or indirect pecuniary or other interest in the proposed transaction considered in this report, including any success or contingency fee or remuneration, other than to receive the cash fee for providing this report. KordaMentha has satisfied the Takeovers Panel, on the basis of the material provided to the Panel, that it is independent under the Takeovers Code for the purposes of preparing this report. Independent New Zealand firm internationally affiliated with KordaMentha Contents 1 Terms of the Proposed Transactions ........................................................................................................................... 2 1.1 Introduction .......................................................................................................................................................... 2 1.2 The Proposed Transactions ................................................................................................................................. 3 1.3 Shareholder Approval .......................................................................................................................................... 4 1.4 Purpose of the Report .......................................................................................................................................... 4 1.5 Other ..................................................................................................................................................................... 5 2 Merits of the Proposed Transactions ........................................................................................................................... 6 2.1 Summary of the merits of the Proposed Transactions ...................................................................................... 6 2.2 Fairness assessment under NZX Listing Rules .................................................................................................. 6 2.3 Orion Health ......................................................................................................................................................... 7 2.4 Valuation of Solution Groups .............................................................................................................................10 2.5 Hg Transaction ...................................................................................................................................................11 2.6 Share Buyback ...................................................................................................................................................12 2.7 Potential outcomes of the Proposed Transactions ..........................................................................................13 2.8 Prospect of alternative transactions to acquire Orion Health .........................................................................15 2.9 Acceptance or rejection .....................................................................................................................................15 3 Profile of Orion Health .................................................................................................................................................16 3.1 Background and History ....................................................................................................................................16 3.2 Business Operations ..........................................................................................................................................17 3.3 Industry Overview ...............................................................................................................................................18 3.4 Group Financial Performance ...........................................................................................................................21 3.5 Rhapsody ............................................................................................................................................................22 3.6 PHM ....................................................................................................................................................................25 3.7 Hospitals .............................................................................................................................................................29 3.8 Group Financial Position ....................................................................................................................................31 3.9 Capital Structure and Ownership ......................................................................................................................32 3.10 Share Price Performance...................................................................................................................................33 4 Valuation ......................................................................................................................................................................34 4.1 Valuation Approach ............................................................................................................................................34 4.2 Rhapsody Valuation ...........................................................................................................................................35 4.3 PHM Valuation ...................................................................................................................................................39 4.4 Hospitals Valuation ............................................................................................................................................40 4.5 Hg Transaction ...................................................................................................................................................41 4.6 Share Buyback ...................................................................................................................................................43 Appendix 1: Sources of Information ....................................................................................................................................44 Appendix 2: Qualifications and Declarations ......................................................................................................................45 Appendix 3: Valuation Methodologies .................................................................................................................................46 Appendix 4: Valuation Evidence ..........................................................................................................................................47 Appendix 5: Glossary of Key Terms and Definitions ...........................................................................................................56 Page 1 1 Terms of the Proposed Transactions 1.1 Introduction Orion Health Group Limited (Orion Health or the Company) is a New Zealand incorporated company listed on the NZX Main Board. It is a provider of healthcare information technology (IT). Orion Health’s operations span three business units (each deemed a Solution Group): • Rhapsody: An integration solution which allows complex healthcare systems to seamlessly connect with one another. • Population Health Management (PHM): Provides software that aggregates and allows for the analysis of health data from a diverse set of sources such as General Practitioners, Specialists and Hospitals. • Hospitals: Offers software solutions that assist with the administration of hospitals. Orion Health’s largest shareholder is McCrae Limited, which is associated with Orion Health’s founder and Managing Director Ian McCrae. McCrae Limited and associated parties own 50.5% of the fully paid ordinary shares in Orion Health (Shares). Orion Health has announced a relatively complex transaction (the Hg Transaction), which would result in the sale of 75.1% of Rhapsody and 24.9% of PHM to ‘Mercury 2 Fund’, a vehicle managed by HgCapital LLP (Hg). Hg is a private equity firm with approximately GBP 10 billion funds under management. Hg has offices in London and Munich and serves more than 100 highly regarded institutional investors, including private and public pension funds, endowments, insurance companies and fund of funds. Orion Health has announced that on completion of the Hg Transaction, it would undertake a share buyback, at an estimated price range of $1.16–$1.26 per share (the Share Buyback). It is anticipated that the Share Buyback would occur by December 2018. The approval of the Hg Transaction and Share Buyback are cross-conditional, so either both are approved or neither will occur. In this report, we refer to the Hg Transaction and the Share Buyback together as ‘the Proposed Transactions’. The Proposed Transactions will effectively give Orion Health shareholders the option to: • Sell their existing Shares for cash consideration, estimated to be in the range of $1.16–$1.26 per share, with the ultimate price dependant on Orion Health’s available cash following completion of the Hg Transaction. • Remain a shareholder of ‘New Orion’, which will own: − 24.9% of Rhapsody − 75.1% of PHM − 100% of Hospitals. • Partially exit